Cargando…

The shaping and functional consequences of the dosage effect landscape in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is a malignant proliferation of plasma B cells. Based on recurrent aneuploidy such as copy number alterations (CNAs), myeloma is divided into two subtypes with different CNA patterns and patient survival outcomes. How aneuploidy events arise, and whether they contri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samur, Mehmet K, Shah, Parantu K, Wang, Xujun, Minvielle, Stéphane, Magrangeas, Florence, Avet-Loiseau, Hervé, Munshi, Nikhil C, Li, Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3907079/ https://www.ncbi.nlm.nih.gov/pubmed/24088394 http://dx.doi.org/10.1186/1471-2164-14-672

Ejemplares similares

Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles
por: Li, Yingxiang, et al.
Publicado: (2013)

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
por: Aktas Samur, Anil, et al.
Publicado: (2022)

Deciphering the chronology of copy number alterations in Multiple Myeloma
por: Aktas Samur, Anil, et al.
Publicado: (2019)

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
por: Samur, Mehmet Kemal, et al.
Publicado: (2020)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

The dChip survival analysis module for microarray data
por: Amin, Samir B, et al.
Publicado: (2011)

Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2018)

Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma
por: Amin, Samirkumar B., et al.
Publicado: (2014)

The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability
por: Derrien, Jennifer, et al.
Publicado: (2021)

Logic programming reveals alteration of key transcription factors in multiple myeloma
por: Miannay, Bertrand, et al.
Publicado: (2017)

Genomic landscape and chronological reconstruction of driver events in multiple myeloma
por: Maura, Francesco, et al.
Publicado: (2019)

Expressed fusion gene landscape and its impact in multiple myeloma
por: Cleynen, A., et al.
Publicado: (2017)

Genomic patterns of progression in smoldering multiple myeloma
por: Bolli, Niccolò, et al.
Publicado: (2018)

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma
por: Alberge, Jean-Baptiste, et al.
Publicado: (2020)

canEvolve: A Web Portal for Integrative Oncogenomics
por: Samur, Mehmet Kemal, et al.
Publicado: (2013)

Constraints on signaling network logic reveal functional subgraphs on Multiple Myeloma OMIC data
por: Miannay, Bertrand, et al.
Publicado: (2018)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
por: Fulciniti, Mariateresa, et al.
Publicado: (2018)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups
por: Bolli, Niccolo, et al.
Publicado: (2018)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Transcription factor-pathway co-expression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma
por: Wang, Xujun, et al.
Publicado: (2013)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
por: Chari, Ajai, et al.
Publicado: (2020)

A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
por: Bolli, N, et al.
Publicado: (2016)

Integrative analysis of gene and miRNA expression profiles with transcription factor–miRNA feed-forward loops identifies regulators in human cancers
por: Yan, Zhenyu, et al.
Publicado: (2012)

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma
por: Bolli, Niccolo, et al.
Publicado: (2014)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

S186: ACQUIRED RESISTANCE TO BISPECIFIC ANTIBODIES BY GENETIC OR EPIGENETIC INACTIVATION OF THE TARGET IN MULTIPLE MYELOMA
por: Derrien, Jennifer, et al.
Publicado: (2023)

Role of apurinic/apyrimidinic nucleases in the regulation of homologous recombination in myeloma: mechanisms and translational significance
por: Kumar, Subodh, et al.
Publicado: (2018)

Biological and prognostic impact of APOBEC-induced mutations in the spectrum of plasma cell dyscrasias and multiple myeloma cell lines
por: Maura, F, et al.
Publicado: (2018)

Nucleotide excision repair is a potential therapeutic target in multiple myeloma
por: Szalat, R, et al.
Publicado: (2018)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Exploring the impact of dexamethasone on gene regulation in myeloma cells
por: Bessonneau-Gaborit, Victor, et al.
Publicado: (2023)

Dysregulated APOBEC3G causes DNA damage and promotes genomic instability in multiple myeloma
por: Talluri, Srikanth, et al.
Publicado: (2021)

Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities
por: Giesen, Nicola, et al.
Publicado: (2022)

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma
por: Lemaitre, Léa, et al.
Publicado: (2020)

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma
por: Cormier, Françoise, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_o57l0ka6e2htkq3a7dacj7rokq